Rafferty Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34M Sell
156,378
-59,740
-28% -$13.3M 0.14% 85
2025
Q4
$49.4M Sell
216,118
-18,012
-8% -$4.1M 0.17% 80
2025
Q3
$54.2M Sell
234,130
-2,784
-1% -$567K 0.18% 77
2025
Q2
$44M Buy
236,914
+22,485
+10% +$4.18M 0.15% 82
2025
Q1
$44.9M Sell
214,429
-62,957
-23% -$12.2M 0.19% 69
2024
Q4
$49.3M Buy
277,386
+11,042
+4% +$2.03M 0.17% 75
2024
Q3
$52.6M Sell
266,344
-35,647
-12% -$6.65M 0.18% 68
2024
Q2
$51.8M Buy
301,991
+68,502
+29% +$11.3M 0.19% 63
2024
Q1
$42.5M Sell
233,489
-6,385
-3% -$1.1M 0.16% 69
2023
Q4
$37.2M Sell
239,874
-4,049
-2% -$590K 0.16% 75
2023
Q3
$36.4M Buy
243,923
+13,173
+6% +$1.93M 0.21% 59
2023
Q2
$31.1M Buy
230,750
+27,121
+13% +$3.98M 0.18% 70
2023
Q1
$32.5M Buy
203,629
+2,013
+1% +$308K 0.22% 66
2022
Q4
$32.6M Buy
201,616
+57,947
+40% +$8.89M 0.27% 61
2022
Q3
$19.3M Buy
143,669
+74,096
+107% +$10.6M 0.21% 83
2022
Q2
$10.7M Sell
69,573
-20,343
-23% -$3.11M 0.1% 127
2022
Q1
$14.6M Sell
89,916
-11,537
-11% -$1.68M 0.09% 142
2021
Q4
$13.7M Buy
101,453
+15,900
+19% +$1.88M 0.07% 148
2021
Q3
$9.23M Buy
85,553
+26,394
+45% +$3.02M 0.06% 171
2021
Q2
$6.66M Sell
59,159
-5,633
-9% -$634K 0.04% 255
2021
Q1
$7.01M Buy
64,792
+26,249
+68% +$2.81M 0.05% 223
2020
Q4
$4.13M Sell
38,543
-15,949
-29% -$1.53M 0.04% 268
2020
Q3
$4.77M Buy
54,492
+1,173
+2% +$110K 0.06% 187
2020
Q2
$5.24M Buy
53,319
+34,255
+180% +$3.02M 0.07% 165
2020
Q1
$1.45M Sell
19,064
-65,533
-77% -$5.58M 0.06% 200
2019
Q4
$7.49M Sell
84,597
-10,004
-11% -$831K 0.12% 101
2019
Q3
$7.16M Buy
94,601
+23,052
+32% +$1.58M 0.11% 100
2019
Q2
$5.2M Buy
71,549
+4,815
+7% +$378K 0.09% 153
2019
Q1
$5.38M Buy
+66,734
New +$5.46M 0.09% 124
2018
Q2
Sell
-32,978
Closed -$3.12M 649
2018
Q1
$3.12M Buy
+32,978
New +$3.62M 0.05% 199
2017
Q4
Sell
-46,336
Closed -$4.12M 700
2017
Q3
$4.12M Buy
+46,336
New +$3.53M 0.09% 115
2017
Q2
Sell
-7,418
Closed -$483K 545
2017
Q1
$483K Buy
7,418
+205
+3% +$12.9K 0.01% 486
2016
Q4
$452K Sell
7,213
-50,229
-87% -$3.07M 0.02% 331
2016
Q3
$3.62M Buy
57,442
+47,803
+496% +$3.09M 0.13% 55
2016
Q2
$597K Sell
9,639
-2,638
-21% -$161K 0.04% 313
2016
Q1
$701K Sell
12,277
-872
-7% -$48.6K 0.04% 351
2015
Q4
$779K Sell
13,149
-2,053
-14% -$118K 0.09% 282
2015
Q3
$827K Buy
15,202
+12,158
+399% +$791K 0.07% 265
2015
Q2
$205K Buy
+3,044
New +$199K 0.01% 504
2014
Q4
Sell
-3,500
Closed -$202K 351
2014
Q3
$202K Buy
+3,500
New +$194K 0.02% 343

Other funds holding ABBV

Rafferty Asset Management's ABBV Position: Q1 2026 in Review

Rafferty Asset Management reduced its AbbVie (ABBV) stake by 28% in Q1 2026, selling an estimated $13.3M and leaving 156,378 shares worth $34M. The position accounts for 0.14% of the portfolio, ranked #85.

Rafferty Asset Management first reported a position in ABBV in Q3 2014 and has held it in 40 quarters since. The position peaked at $54.2M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Rafferty Asset Management held 156,378 shares of AbbVie worth $34M as of Q1 2026.
  • Rafferty Asset Management sold 59,740 AbbVie shares in Q1 2026, an estimated $13.3M.
  • AbbVie made up 0.14% of Rafferty Asset Management's portfolio in Q1 2026, its #85 holding.
  • Rafferty Asset Management first reported a position in AbbVie in Q3 2014 and has held it in 40 quarters since.
  • Rafferty Asset Management's AbbVie position peaked at $54.2M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.